NCT07311135 Accuracy of Smartwatches in Measuring Oxygen Levels in Patients With Pulmonary Hypertension: A Pilot Study
| NCT ID | NCT07311135 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Golden Jubilee National Hospital |
| Condition | Pulmonary Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-12-17 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-12-17 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to learn how accurate smartwatches are at measuring oxygen levels in patients with a condition called pulmonary hypertension. The main questions it aims to answer are: * How accurate the smartwatches are at measuring oxygen levels when the patient is sitting at rest * How accurate are smartwatches at measuring oxygen levels after exercise * How accurate are smartwatches at measuring oxygen levels after breathing a lower level of oxygen through a mask. Researchers will compare oxygen levels measured through a smartwatch with those checked through a finger probe oxygen monitor and also from a blood sample checked from the artery in the wrist to see if smartwatch oxygen measurements are similar. Participants will: -Attend the hospital once, just for a few hours to collect all the required data.
Eligibility Criteria
Inclusion Criteria: * Aged 18-years old and above. * Diagnosed with pulmonary hypertension by right heart catheterisation showing a baseline mean pulmonary artery pressure \> 20mmHg, PVR \>2 Woods Units. * Able to perform a six-minute walk test (6MWT) * Able to give written informed consent. Exclusion Criteria: * Peripheral arterial disease * Tattoos or skin markings which cover the dorsal wrist. * Resting SpO2 \<88% * Severe concurrent medical condition that would prevent participation in study procedures or with life expectancy \<3 months * Patients with bleeding disorders * Patients on anticoagulation * Except in circumstances where anticoagulation is given solely for historical perceived long term survival benefit for pulmonary arterial hypertension. This patient group could be given the option to come off their anticoagulation for 1 week prior to the study visit if they wished to take part in the study. It could then be restarted the day following the study visit providing there were no bleeding complications related to the arterial line.
Contact & Investigator
Martin Johnson, BA, MBChB(Hons), MD, FRCP
PRINCIPAL INVESTIGATOR
Golden Jubilee National Hospital
Frequently Asked Questions
Who can join the NCT07311135 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07311135 currently recruiting?
Yes, NCT07311135 is actively recruiting participants. Contact the research team at martin.johnson@nhs.scot for enrollment information.
Where is the NCT07311135 trial being conducted?
This trial is being conducted at Glasgow, United Kingdom.
Who is sponsoring the NCT07311135 clinical trial?
NCT07311135 is sponsored by Golden Jubilee National Hospital. The principal investigator is Martin Johnson, BA, MBChB(Hons), MD, FRCP at Golden Jubilee National Hospital. The trial plans to enroll 20 participants.